BN-101A / BioEleven - LARVOL DELTA

Samsung Biologics to offer CDO services for Bio Eleven’s immunotherapy candidate (Korea Biomedical Review) - "Bio Eleven...has signed a contract development organization (CDO) agreement with Samsung Biologics to receive the latter’s help in developing BN-101A, an immunotherapy candidate. Under the accord, Samsung Biologics will provide a full scope of its CDO services, from developing cell lines and manufacturing non-clinical and clinical samples to submitting papers to apply for the investigational new drug...The company has confirmed the anticancer effect in cell and animal experiments compared to existing anticancer drugs and plan to enter a global phase 1 clinical trial by 2022."

Licensing / partnership • New P1 trial • Oncology